Form 4: Intuitive Surgical SVP Mark Brosius Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Mark Brosius, SVP & Chief Manufacturing and Supply Chain Officer at Intuitive Surgical, sold shares of ISRG common stock on May 16 and 17, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Mark Brosius, a Senior Vice President at Intuitive Surgical, sold shares of the company's common stock on May 16 and May 17, 2024.
- The sales were executed under a pre-arranged trading plan that complies with SEC Rule 10b5-1.
- On May 16, 2024, 175 shares were sold at a price of $398.28 per share.
- On May 17, 2024, 63 shares were sold at a price of $396.19 per share.
- Following these transactions, Mr. Brosius directly owns 295 shares of Intuitive Surgical common stock.
Sentiment
Score: 5
Explanation: The document is neutral in sentiment as it simply reports insider trading activity under a pre-existing plan. It doesn't indicate positive or negative performance for the company.
Positives
- The sales were conducted under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Insider sales are a common occurrence in publicly traded companies. The use of a 10b5-1 trading plan suggests that the sales were pre-planned and not based on any material non-public information.
Comparison to Industry Standards
- Comparing these transactions to other insider sales within the medical device industry, the volume of shares sold by Mr. Brosius appears relatively small.
- For example, executives at Stryker or Medtronic often execute larger sales, but these are typically tied to option exercises or other compensation-related events.
- The use of a 10b5-1 plan is a standard practice among executives at companies like Intuitive Surgical to avoid any appearance of impropriety.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders, but the use of a 10b5-1 plan mitigates concerns about insider information.
Key Dates
| Date | Description |
|---|---|
| 05/16/2024 | Sale of 175 shares of common stock at $398.28 per share. |
| 05/17/2024 | Sale of 63 shares of common stock at $396.19 per share. |
| 05/17/2024 | Date of Form 4 filing. |
| 06/07/2024 | Expiration date of the 10b5-1 trading plan. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.